SCHEMBL2435573

SCHEMBL2435573

Oc1ccc(-c2ncc(Cl)cn2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.68
KMT2A Q03164 7/20 0.68
NPC1 O15118 4/20 0.68
RAB9A P51151 4/20 0.68
MAPT P10636 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
TP53 P04637 2/20 0.52
USP2 O75604 1/20 0.52
PKM P14618 1/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
HSD17B10 Q99714 2/20 0.50
ESR2 Q92731 2/20 0.43
ESR1 P03372 1/20 0.43
HDAC4 P56524 2/20 0.43
MAPK1 P28482 2/20 0.42
BCHE P06276 1/20 0.41
DEGS1 O15121 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27513000 0.83 NPC1 (0.55) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL3625738 0.83 MEN1 (0.77) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL2434792 0.82 NPC1 (0.56) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL14422990 0.81 MEN1 (0.82) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL5586458 0.81 NPC1 (1.00) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL12179320 0.78 MEN1 (0.49) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL2439837 0.77 MEN1 (0.68) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL22130253 0.77 RAB9A (0.68) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL12508334 0.77 RAB9A (0.55) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL14295782 0.77 MEN1 (0.68) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4674852-A1 PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE Innovstone Therapeutics Limited (CN) 2026-01-07 EP disclosed
CN-118871444-A Preparation method and application of dihydro-thienopyrimidine derivative 上海翊石医药科技有限公司 2024-10-29 CN disclosed
WO-2024179493-A1 PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE 上海翊石医药科技有限公司 2024-09-06 WO disclosed
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
EP-2694472-A2 SULFONAMIDE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2014-02-12 EP disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed
WO-2012137982-A9 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-14 WO disclosed
WO-2012170371-A1 COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS N30 PHARMACEUTICALS, LLC (US) 2012-12-13 WO disclosed
WO-2012137982-A2 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-11 WO disclosed
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
EP-2364296-A1 PYRROLIDINES Pfizer Limited (GB) 2011-09-14 EP disclosed
WO-2010052625-A1 PYRROLIDINES PFIZER LIMITED (GB) 2010-05-14 WO disclosed
WO-2010052625-A1 PYRROLIDINES PFIZER LIMITED (GB) 2010-05-14 WO disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120793-A1 Pyrrolidines PTGER2, PTGDR2, PTGES2 MEN1 1931/4885KMT2A 834/4885NPC1 4756/4885
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 MEN1 4699/4885KMT2A 542/4885NPC1 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.